Behavior of small cell lung carcinoma in “Hermanos Ameijeiras” hospital

Authors

  • Haslen Hassiul Cáceres Lavernia Hospital "Hermanos Ameijeiras", Ciudad Habana. http://orcid.org/0000-0001-6606-3037
  • Elia Nenínger Vinageras Hospital "Hermanos Ameijeiras", Ciudad Habana.

Keywords:

LUNG NEOPLASMS, CARCINOMA

Abstract

Background: small cell lung carcinoma is approximately in a 15 % of bronchogenic carcinomas. At diagnosis, between 70 and 80 % of patients often show the disease disseminated, so most of the patients die, even with the best treatment available.

Objective: to describe the behavior of small cell lung carcinoma in patients registered in "Hermanos Ameijeiras" hospital in Havana during the years 2010 to 2013.

Methods: a descriptive and retrospective study was carried out in patients diagnosed with small cell lung cancer treated at the oncology department of that hospital from January, 2010 to December, 2013. The universe of study consisted of 1013 patients diagnosed with lung cancer and the sample comprised 104 patients diagnosed with small cell lung carcinoma.

Results: the frequency of small cell lung carcinoma was of a 10,3 % and the predominant age group was 60 to 69 years and in males. The 50 % showed some associated co-morbidity, being hypertension the most frequent one, followed by diabetes mellitus and ischemic heart disease. As the primary site, the right lung prevailed, diagnosed mostly in stage IV, being the liver the most common site of metastasis, followed by the contralateral lung and pleura. The most used treatment was chemotherapy as a single modality or with radiation therapy, reaching a median survival of 7 months.

Conclusions: small-cell lung carcinoma is the less frequent histological variant; most of the patients had the disease disseminated at diagnosis. Chemotherapy improves survival but it is curative in only a minority of patients.

Downloads

Download data is not yet available.

Author Biographies

Haslen Hassiul Cáceres Lavernia, Hospital "Hermanos Ameijeiras", Ciudad Habana.

Especialista de Primer Grado en Oncología. Máster en Infectología.

Elia Nenínger Vinageras, Hospital "Hermanos Ameijeiras", Ciudad Habana.

Especialista Segundo Grado en Oncología. Dra en Ciencias Médicas.

References

Anuario del MINSAP. Ciudad de La Habana: Dirección nacional de estadística. (DNE); 2014.

Johnson David H, Schiller Joan H, Bunn Paul A. Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology [revista en internet]. 2014, abril [citado 28 de enero 2016]; 32(10): 973-982. Disponible en: http://jco.ascopubs.org/content/32/10/973.short.

Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Annals of Oncology [revista en internet]. 2010, Marzo [citado 28 de enero 2016]; 21: 1810–1816. Disponible en: https://annonc.oxfordjournals.org/content/early/2010/03/15/annonc.mdq036.full.

Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler T C, Kaufmann C, Hortig P. A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Annals of Oncology [revista en internet]. 2011, Enero [citado 28 de enero 2016]; 22: 1798–1804. Disponible en: https://annonc.oxfordjournals.org/content/early/2011/01/25/annonc.mdq652.full.

Hann CL, Rudin CM. Management of Small-Cell Lung Cancer: Incremental Changes but Hope for the Future. Oncology [revista en internet]. 2008 [citado 28 de enero 2016]; 22(13): 1486–1492. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19133604.

Cáncer de pulmón de células pequeñas: Información General y Tratamiento. [página en internet]. Instituto Nacional del Cáncer (PDQ); c2008 [actualizado 22 de abril 2015; citado 28 de enero 2016]. Disponible en: http://www.cancer.gov.

National Comprehensive Cancer Network. [página en internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®). Survivorship; c2016 [actualizado 27 de febrero 2015; citado 15 de mayo 2015]. v.1.c2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Neninger Vinageras E, del Castillo Carrillo C, Viada C, Barbán Suárez R, Gassiot Nuño C, González González J. Tratamiento del carcinoma de células pequeñas del pulmón y supervivencia a 5 años. Rev cubana med [revista en internet]. 2008 [citado 28 de enero 2016]; 47(4). Disponible en: http://www.bvs.sld.cu/revistas/med/vol47_4_08/med08408.htm.

Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124. J Clin Oncol [revista en internet]. 2009 [citado 28 de enero 2016]; 27(15): 2530-2535. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19 349543.

Hernández Hernández J, Moreno de Vega Herrero M. Tratamiento del cáncer de pulmón en pacientes ancianos. Medicina respiratoria [revista en internet]. 2014 [citado 28 de enero 2016]; 7(2): 51-64. Disponible en: http://www.neumologiaysalud.es/descargas/R7/R72-6.pdf.

Cortés-Funes H, Colomer Bosch R. Tratado de Oncología Médica. 2da ed. En: Pilar Garrido López, Mercedes Murcia Simón, Elena López Miranda. Carcinoma Microcítico de Pulmón. Madrid: Aventis; 2009. p. 661-676.

Nobuhiro A, Yoshihiro O, Norihiro K, Etsuro Y, Akihito K. Relapse Small Cell Lung Cancer. Ther Adv Med Oncol [revista en internet]. 2014 [citado 28 de enero 2016]; 6(2): 69-82. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932054/.

Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-estage small cell lung cancer: a study of 284 patients. Lung Cancer [revista en internet]. 2010 [citado 28 de enero 2016]; 67(2): 221-226. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19497635.

Willian N, William Jr, Gil Ferreira C, Rocha Cruz M, C. Buzaid A. Capitulo II Pulmón. Células Pequeñas. p. 107-115. En: Carlos Buzaid A, Cotait Maluf F. Manual de Oncología Clínica de Brasil. 7a ed. Sao Paulo: Dendrix; 2013.

Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, on behalf of the ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [revista en internet]. 2013 [citado 28 de enero 2016]; 24(Suppl6): 99–105. Disponible en: http://annonc.oxfordjournals.org/content/early/2013/06/26/annonc.mdt178.extract.

Blackhall F, Shepherd F. Small cell lung cancer and targeted therapies. Curr Opinn Oncol [revista en internet]. 2007 [citado 28 de enero 2016]; 19(2): 103-108. Disponible en: http://journals.lww.com/co-oncology/Abstract/2007/03000/Small_cell_lung_cancer_and_targeted_therapies.7.aspx.

Downloads

Published

2016-02-02

How to Cite

1.
Cáceres Lavernia HH, Nenínger Vinageras E. Behavior of small cell lung carcinoma in “Hermanos Ameijeiras” hospital. Rev. electron. Zoilo [Internet]. 2016 Feb. 2 [cited 2025 Sep. 11];41(2). Available from: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/630

Issue

Vol. 41 No. 2 (2016): February

Section

Original articles

License

This journal provides free and immediate access to its content under the principle that making research freely available to the public supports a greater exchange of global knowledge. This means that the authors transfer the copyright to the journal, so that copies and distribution of the contents can be made by any means, as long as the authors' acknowledgment is maintained. These terms are a reflection that the journal assumes copyright under Creative Commons licenses, specifically under a Creative Commons Attribution 4.0 International license.

Registration and submission of articles to the journal is free. The processing, including review, editing and publication, is completely free of charge.